Ken Fisher’s Sage Therapeutics SAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-432,545
Closed -$3.12M 1007
2024
Q3
$3.12M Sell
432,545
-3,876
-0.9% -$35.5K ﹤0.01% 533
2024
Q2
$4.74M Buy
436,421
+3,952
+0.9% +$50.6K ﹤0.01% 494
2024
Q1
$8.1M Buy
432,469
+544
+0.1% +$12.5K ﹤0.01% 449
2023
Q4
$9.36M Buy
431,925
+32,306
+8% +$640K ﹤0.01% 421
2023
Q3
$8.22M Sell
399,619
-31,527
-7% -$911K ﹤0.01% 455
2023
Q2
$20.3M Buy
431,146
+10,229
+2% +$509K 0.01% 371
2023
Q1
$17.7M Sell
420,917
-17,659
-4% -$759K 0.01% 380
2022
Q4
$16.7M Sell
438,576
-6,238
-1% -$238K 0.01% 374
2022
Q3
$17.4M Buy
+444,814
New +$17.2M 0.01% 350

Other funds holding SAGE

Ken Fisher's SAGE Position: Q4 2024 in Review

Ken Fisher sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 432,545 shares — an estimated $3.12M sold.

Ken Fisher first reported a position in SAGE in Q3 2022 and held it in 9 quarters. The position peaked at $20.3M in Q2 2023. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • Ken Fisher reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Ken Fisher sold 432,545 Sage Therapeutics shares in Q4 2024, an estimated $3.12M.
  • Ken Fisher first reported a position in Sage Therapeutics in Q3 2022 and held it in 9 quarters.
  • Ken Fisher's Sage Therapeutics position peaked at $20.3M in Q2 2023.
  • 177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Fisher Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.